In a filing, Akero Therapeutics Inc revealed its President and CEO Cheng Andrew unloaded Company’s shares for reported $2.04 million on Jun 10 ’25. In the deal valued at $54.05 per share,37,837 shares were sold. As a result of this transaction, Cheng Andrew now holds 556,487 shares worth roughly $31.02 million.
Then, Rolph Timothy sold 2,358 shares, generating $127,323 in total proceeds. Upon selling the shares at $54.00, the Chief Scientific Officer now owns 167,363 shares.
Before that, White William Richard sold 2,804 shares. Akero Therapeutics Inc shares valued at $151,402 were divested by the Chief Financial Officer at a price of $53.99 per share. As a result of the transaction, White William Richard now holds 59,155 shares, worth roughly $3.3 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock jump 0.23% to $55.75. Over the last five days, the stock has gained 1.90%. Akero Therapeutics Inc shares have risen nearly 100.40% since the year began. Nevertheless, the stocks have risen 129.52% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $21.02 was recorded on 01/14/25.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 53.99, which if violated will result in even more drops to 52.23. On the upside, there is a resistance level at 56.65. A further resistance level may holdings at 57.56.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
